At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 181 enrolled
Drug / intervention
exenatide +2 moredrug
Likely dose
exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled
In Brief
A Phase 3 clinical trial evaluating exenatide and placebo for Type 2 Diabetes. Completed, enrolled 181 participants across 12 sites.
Detailed Summary
This long term, placebo-controlled trial is intended to assess the efficacy and safety of exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with oral antidiabetic(s) but not well controlled.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesJapan
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2007
Enrollment StartJan 2008
Primary CompletionNov 2008
TodayJul 2026
First PostedDec 20, 2007
Enrollment StartJan 1, 2008
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.5 years ago
Interventions
exenatidedrug
subcutaneous injection, 5mcg, twice a day
exenatidedrug
subcutaneous injection, 10mcg, twice a day
placebodrug
subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day